The licensing agreement grants BlissBio the exclusive right to use the eribulin-linker payload to develop a therapeutic antibody-drug conjugate (ADC) against an undisclosed oncology target for the China market.
The licensing agreement includes an upfront payment, milestones and sales royalty payments, which are undisclosed.
BlissBio has an exclusivity option to expand the territory beyond China to the global market and to develop therapeutic ADCs to two additional undisclosed oncology targets.
Morphotek's ADC services offer third parties the opportunity to license the proprietary eribulin-linker payload to develop investigational ADCs using either Morphotek's REsidue-SPEcific Conjugation Technology (RESPECT) or an alternative approach to conjugation.
Morphotek, a subsidiary of Eisai Inc., is focused on developing novel classes of biological-based products to treat cancer, inflammatory, and infectious diseases. Its mission is to develop novel targeted therapies that attack underlying disease pathways, and in oncology indications, that can overcome the immunosuppressive effects by tumors on immune-mediated experimental therapies.
BlissBio is focusing on discovery, development and commercialization of biotherapeutics for unmet medical needs. The company has developed a pipeline engaging multiple technology platforms through collaborations with domestic and foreign biopharmaceutical companies.
Tokyo, Japan-based global research and development-based pharmaceutical company Eisai Co., Ltd. has over 10,000 employees working across its global network of R and D facilities, manufacturing sites, and marketing subsidiaries.The company strives to deliver innovative products in various therapeutic areas with high unmet medical needs, including neurology and oncology.
Artios Pharma elects Rajesh Chopra PhD as non-executive director
First Subject Dosed with Monoclonal Antibody Encoded by mRNA in a Clinical Trial
Ligand Invests USD 3m in Dianomi Therapeutics
Antibe Therapeutics Enters CDN 5m Bought Deal Offering
Can-Fite Receives Notice of Allowance from US Patent and Trademark Office for Osteoarthritis Drug
KalVista Pharmaceuticals Names Pereira to Board of Directors
Innovus Pharma Launches OTC Hemorrhoid Xyralid Suppositories in Canada